Fluent Essays

Need this done with professor plagiarism report. WIll pay well, must be done in 3 days. I will provide a sample paper too once I accept a bid  DESCRIPTION You are the lead scientist on a pharmaceutical research & development (R&D) team that has developed a new drug to treat disease. As the principal investigator you will write a short paper on the design and efficacy (effectiveness) of the new pharmacological product. Although the drug is imaginary, it must be targeted against a known disease. You can select a pathological condition that affects the physiology of at least one of the following systems:  • Nervous/Neuromuscular/Muscle  • Endocrine  • Cardiovascular  • Respiratory  • Gastrointestinal  • Urinary   The paper must contain the following components:  1. Name of the drug. You can be creative with the invented name but it should relate to the function of the product, e.g., Inhibitol (if the drug has an inhibitory effect on its target)  2. Paper Title. Again, originality is encouraged but the title must contain the product name and the disease condition it treats.  3. Pathophysiology. This is the research component of the paper. The cause(s) (etiology), symptoms and effects of the disease should be adequately described. The pathophysiology of your selected illness must include a description of the disease mechanism on a molecular level (participant biomolecules such as enzymes, receptors, hormones, neurotransmitters, etc.). This part of the paper should be well referenced primarily using scientific/medical literature. Avoid citing websites such as WebMD, although government agency websites such as the NIH, CDC, WHO, etc. are permitted.  4. Drug Design & Efficacy. How does your invented drug work to effectively treat the disease condition? Your description should be consistent with molecular mechanisms of the disease and should involve ligand-based binding to principal targets implicated in the process.  5. Side Effects. Based on the biomolecule(s) targeted by the designed drug, you should be able predict possible side effects, e.g., Inhibitol inhibits the activity of the enzyme acetylcholinesterase at neuromuscular junctions. This increases the amount and duration of ACh in the NMJ, which helps to improve muscle signaling in myasthenia gravis but may cause spastic paralysis due to neurotransmitter overabundance. Side effects should relate to the specific activity of your drug.   Your paper should be 3 – 4 pages in length (min: 3, max: 4) typed, 1.5-spaced 12-pt font. A bibliography is REQUIRED and is not included in your page count. Do not add cover pages, photos, charts or diagrams to your paper. This is an assessment of your original writingName: Course: PCB4097 Semester: Spring 2016 Instructor: Prof. S. Williams Drug name: Areinhiterol Title: Design and Efficacy of Areinhiterol in the Management of Asthma. Pathophysiology Asthma is a reversible chronic inflammatory and obstructive disease of the respiratory system. It is associated with episodes of airway inflammation and narrowing leading to symptoms of bronchospasm and airway obstruction. Narrowing results from the mucosal inflammation and the associated increased contraction of the smooth muscles and the increased mucus production. There is also increased the presence of eosinophils as the lamina reticularis also thickens. With chronicity, the smooth muscle might eventually hypertrophy with hyperplasia of the mucous glands. The immune cells and modulators as chemokines, leukotrienes, histamine, and cytokines are also involved (Ortega, 2014). Affected individuals report varying episodes characterized mainly by wheezing, breathlessness, chest tightness and coughing that define a typical asthmatic attack. Sometimes the individual may report thick sputum production which sometimes may seem pus-like. Symptoms worsen early in the morning, late in the evening or in association with cold or strenuous exercise. The disease is diagnosed by its classical clinical symptoms, through spirometry and response to bronchodilators. Most people associate the disease with both environmental and genetic causes. The environmental factors are mainly linked to allergens like dust mites and other pollutants and environmental chemicals. Besides certain drugs like beta blockers, acetaminophen and aspirin have been incriminated. Some individuals have also been shown to be genetically predisposed to the disease in what is referred to as atopy. History of atopic diseases as atopic conjunctivitis, rhinitis and PHARMACEUTICAL RESEARCH 2 eczema increase an individuals risk for asthma development. Different inheritable genes have been associated with the development of asthma. The genes are mostly linked to inflammation and immune modulating processes. Such individuals will mostly develop type I hypersensitivity reactions. A combination of gene susceptibility and the environmental factors increase the risk especially in these genetically [predisposed individuals. Currently, the disease has no cure and the management targets to prevent episodes of asthmatic attack or to alleviate symptoms and restore airway patency. Management also encourages individuals to avoid coming into contact with the various allergens and other triggers (Ortega, 2014). Drug Mechanisms Areinhiterol is a selective beta-2 adrenergic receptor (AR) agonist owing to its tertiary butyl group. The drug can be used both as a symptom-reliever and as a disease-controller. Bronchodilation of the airway smooth muscle is a function of the sympathetic nervous system. The human airway smooth muscle has not been shown to have